First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.
about
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesThe Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal ResearchInference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM.Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX.Development of Targeted Therapies in ErbB2-Positive Breast CancerDiscovering tumor suppressor genes through genome-wide copy number analysis.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenograftsIxabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.Clinical experience with trastuzumab (herceptin).Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancerRecombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agentChallenges facing adjuvants for cancer immunotherapy.External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.Combining radiotherapy and immunotherapy: a revived partnership.Treatment of elderly cancer patients with chemotherapy.The role of Herceptin in early breast cancerActivator protein-2 in carcinogenesis with a special reference to breast cancer--a mini review.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.Recent advances in the molecular characterization of circulating tumor cells.Optical imaging in cancer research: basic principles, tumor detection, and therapeutic monitoring.Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies.RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.Targeting protein quality control pathways in breast cancer.The Dawning of Translational Breast Cancer: From Bench to Bedside.In vitro detection of human breast cancer cells (SK-BR3) using herceptin-conjugated liquid crystal microdroplets as a sensing platform.Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.
P2860
Q24650717-A376ADEE-C029-4796-818A-AF19DCDFB8C4Q28379612-C0BEB90E-8314-4B6F-8CE6-325C143CF819Q33597322-B256D4F0-3B23-4870-A101-567B11D6E7B0Q33991887-53638EE8-CAE9-4817-9965-02FA07D5B588Q34095743-28E62F1B-0150-4523-804B-BA05659B7FAEQ34152841-0EE815E8-750A-4948-97C5-83EF4DCAD380Q34664078-9C888BD2-7CCA-405E-8E84-DD1BA53C4F25Q34694605-AF176238-F1FE-40D3-A3F5-8D41AB190D4DQ34788890-222B6EFE-D34F-4884-8A8D-C649C0255D85Q35274741-33C03CB6-3E3F-4214-83D4-D7F23BC2B77AQ35583405-AAF5B9B2-90E9-4C36-B86C-67116D541BDEQ35584641-89B38CF8-8E62-4193-8E5A-07007CD5E7EDQ35586920-A253716A-ED8C-404A-8EF5-78D150F224C7Q35953773-BB6C6C10-6B20-4856-8E07-5ABB53B5B7A0Q36017256-A4C5F54F-5988-4094-A1F7-7CB49DA3FD23Q36274581-585AC55D-B975-42A7-866F-C70E54EF21A3Q36276360-56E63C13-A4BF-417B-BC07-4D14AE840824Q36657407-A0B25724-0D99-4563-9199-D6AB4A941FC3Q36748207-B07FCB08-A248-49D4-98F2-A7A286A68838Q36860992-76AECBE5-A561-41DE-A944-C77DAECBB3F5Q37693504-1432130E-52FC-4A92-AFD8-B892ADC29B74Q37901290-7E2784D1-17AC-4420-81D5-10C912A2E964Q38100711-2E0F0407-C0B1-4298-9F66-BD1C1A42C59BQ39207741-07C4C560-960C-4F2A-A910-C9FFD0FA3C0CQ39753797-55F8FC61-A3DE-4422-A336-6A8DDA4E27EAQ39841379-DC98C543-C526-4DF4-A383-DAB5C2C10AC4Q40133703-B64F17C7-7E68-4CA5-820E-0FFDACAA5986Q40303131-41E72CF7-38FD-4E1D-BA92-5EF03351F396Q44503403-3CE70B0D-1C56-46AF-8415-C52EB5BDC7D7Q46087491-E38FC9B2-9166-41A6-87BF-10917E2693D7Q49544424-24D83825-1442-4DF3-8A3B-5FA183C80176Q51196083-83813600-3AD7-42BA-8AAB-3862C38490EDQ52936283-0EAEF9EB-3BB3-48C5-841D-458B999CC49B
P2860
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
First-line, single-agent Herce ...... cancer: a preliminary report.
@ast
First-line, single-agent Herce ...... cancer: a preliminary report.
@en
First-line, single-agent Herce ...... cancer: a preliminary report.
@nl
type
label
First-line, single-agent Herce ...... cancer: a preliminary report.
@ast
First-line, single-agent Herce ...... cancer: a preliminary report.
@en
First-line, single-agent Herce ...... cancer: a preliminary report.
@nl
prefLabel
First-line, single-agent Herce ...... cancer: a preliminary report.
@ast
First-line, single-agent Herce ...... cancer: a preliminary report.
@en
First-line, single-agent Herce ...... cancer: a preliminary report.
@nl
P2093
P1476
First-line, single-agent Herce ...... cancer: a preliminary report.
@en
P2093
D J Slamon
D Tripathy
Genentech H0650 study investigators
J C Gutheil
L Fehrenbacher
L N Harris
M A Cobleigh
M Burchmore
P356
10.1016/S0959-8049(00)00405-6
P478
37 Suppl 1
P577
2001-01-01T00:00:00Z